Tiamenidine (Hoe 440) , a new antihypertensive substance
Lindner, E.; Kaiser, J.
Archives Internationales de Pharmacodynamie et de Therapie 211(2): 305-325
1974
ISSN/ISBN: 0003-9780 PMID: 4460920 Document Number: 73830
Document emailed within 1 workday
Related Documents
Gerlis, L.S.; Wright, N. 1980: Abrupt withdrawal of the antihypertensive agent tiamenidine after 12-months' treatment Pharmatherapeutica 2(6): 408-411Landheim, A.S.; Bakken, K.; Vaglum, P. 2006: What characterizes substance abusers who commit suicide attempts? Factors related to Axis i disorders and patterns of substance use disorders. a study of treatment-seeking substance abusers in Norway European Addiction Research 12(2): 102-108
Shoji, M.; Harigaya, Y.; Okamoto, K.; Yamaguchi, H.; Hirai, S. 1988: The study of neuroactive substance within senile plaques--with special reference to somatostatin and substance P Rinsho Shinkeigaku 28(1): 67-73
Browne, F.A.; Wechsberg, W.M. 2010: The intersecting risks of substance use and HIV risk among substance-using South African men and women Current Opinion in Psychiatry 23(3): 205-209
Floyd, L.J.; Hedden, S.; Lawson, A.; Salama, C.; Moleko, A.Gloria.; Latimer, W. 2010: The association between poly-substance use, coping, and sex trade among black South African substance users Substance use and Misuse 45(12): 1971-1987
Farmer, R.F.; Kosty, D.B.; Seeley, J.R.; Gau, J.M.; Klein, D.N. 2019: Family Aggregation of Substance use Disorders: Substance Specific, Nonspecific, and Intrafamilial Sources of Risk Journal of Studies on Alcohol and Drugs 80(4): 462-471
Whitesell, N.Rumbaugh.; Beals, J.; Mitchell, C.M.; Manson, S.M.; Turner, R.Jay.; Big Crow, C.K.; Buchwald, D.; Chambers, B.; Christensen, M.L.; Dillard, D.A.; DuBray, K.; Espinoza, P.A.; Fleming, C.M.; Wilson Frederick, A.; Gone, J.; Gurley, D.; Jervis, L.L.; Jim, S.M.; Kaufman, C.E.; Klein, S.A.; Lee, D.; Manson, S.M.; McNulty, M.C.; Middlebrook, D.L.; Moore, L.A.; Nez, T.D.; Norton, I.M.; Novins, D.K.; O'Nell, T.; Orton, H.D.; Randall, C.J.; Sam, A.; Shore, J.H.; Simpson, S.G.; Yazzie, L. 2009: Childhood exposure to adversity and risk of substance-use disorder in two American Indian populations: the meditational role of early substance-use initiation Journal of studies on alcohol and drugs 70(6): 971-981
Fisun, A.I.; Kuvshinov, K.É; Shamreĭ, V.K.; Alekseev, V.V.; Goncharenko, A.I.; Pastushenkov, A.V.; Tikhenko, V.V. 2014: Prophylaxis of substance abuse in the Armed Forces: organization and performance of screening. Problem of substance dependence disorders is the actual for many countries in the world and affects on health of servicemen Voenno-Meditsinskii Zhurnal 335(3): 4-12
1999: Center for Mental Health Services; Center for Substance Abuse Treatment; fiscal year 1999 funding opportunity. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services (CMHS), Center for Substance Abuse Treatment (CSAT). Notice of availability of funds for cooperative agreements for CMHS/CSAT collaborative program on homeless families: women with psychiatric, substance u Federal register 64(108): 30350-30352
Velázquez, R.A.; Kitto, K.F.; Larson, A.A. 1997: CP-96,345, which inhibits [3H] substance P binding, selectively inhibits the behavioral response to intrathecally administered N-methyl-D-aspartate, but not substance P, in the mouse Journal of Pharmacology and Experimental Therapeutics 281(3): 1231-1237
1990: American Academy of Pediatrics Provisional Committee on Substance Abuse: Selection of substance abuse treatment programs Pediatrics 86(1): 139-140
Okamoto, Y.; Shirotori, K.; Kudo, K.; Ishikawa, K.; Ito, E.; Togawa, K.; Saito, I. 1993: Cytokine expression after the topical administration of substance P to human nasal mucosa. the role of substance P in nasal allergy Journal of Immunology 151(8): 4391-4398
Dickerson, L.M.; Carek, P.J. 2002: Are new antihypertensive agents better than old antihypertensive agents in preventing cardiovascular complications? Journal of Family Practice 51(1): 9
Chen, Y.Q. 1983: An anticancer fluorescent substance in the human urine. II. Biological properties of an anticancer fluorescent substance Zhonghua Zhong Liu Za Zhi 5(4): 266-269
Pedersen, J.M. 1994: Substance abuse among school children in Greenland in 1992. a nation-wide follow-up study of substance abuse habits among school children Ugeskrift for Laeger 156(27): 4036-4038
Falkenhein, S.F.; Macdonald, H.; Huber, M.M.; Koch, D.; Parker, C.W. 1980: Effect of the 5-hydroperoxide of eicosatetraenoic acid and inhibitors of the lipoxygenase pathway on the formation of slow reacting substance by rat basophilic leukemia cells; direct evidence that slow reacting substance is a product of the lipoxygenase pathway Journal of Immunology 125(1): 163-168
Yoshida, K.; Wago, K. 1981: Studies on the clinical significance of a simple fluorometric determination method of thiobarbituric acid reactive substance levels in human urine--urinary thiobarbituric acid reactive substance levels in hemiplegia and rheumatoid arthritis Rinsho Byori. Japanese Journal of Clinical Pathology 29(1): 87-89
Outzen, K.E.; Svane-Knudsen, V. 1993: Effect of surface-active substance on nasal mucociliary clearance time: a comparison of saccharin clearance time before and after the use of surface-active substance Rhinology 31(4): 155-157
Kratz, F. 1978: Microsomal oxidative foreign-substance degradation by the human liver. Oxidative foreign-substance degradation by microsomal fractions of the liver withdrawn by needle biopsy, illustrated on the example of coumarin-7-hydroxylase and 7-ethoxycoumarin hydroxylase in persons with healthy livers and various liver diseases Fortschritte der Medizin 96(8): 393-397
Vorburger, C.; Tuckman, J. 1972: New antihypertensive drugs Schweizerische Medizinische Wochenschrift 102(30): 1033-1039